Post stabilisation and successful venturing into commercial manufacturing, Syngene will be the only listed company in India having exclusive focus on NMEs and catering to the entire lifecycle of an NME….Since PI (CSM) & Divis operate with a similar model but lakc the presence in entire lifecycle, it is my personal expectation that Syngene should trade at premium to both the said companies. I can be wrong in my assessment.
Syngene is not a full fledged pharma company but is like a service-oriented company catering to pharmaceutical sector apart from others. To understand the segment in which Syngene is operating in, apart from company’s own past ARs as well as RHP, you can refer to past ARs of its Indian peers like GVK as also presentations, ARs and brokerage reports of its international peers like Wuxi.
Once any company’s management falters in walking the talk, I stop actively tracking the company as management quality and conduct is the highest weightage I put during my investment decision.
| Subscribe To Our Free Newsletter |
